Biological Characteristics of Mycoplasma and Laboratory Control Strategies

Mycoplasma combines pathogenicity with a highly cryptic lifestyle; in the clinical setting it can cause respiratory and urogenital tract infections, while in cell culture systems it is one of the most common occult contaminants. A systematic understanding of its biological characteristics, together with the establishment of a closed-loop “detection–eradication–prevention–environmental decontamination” management scheme in the laboratory, is essential for ensuring the quality of cell-based experiments and related products.

I. Overview of Mycoplasma

1.1 Basic Biological Features

(1) Mycoplasma are small, cell wall–less prokaryotes whose outer boundary consists solely of a sterol-containing lipid bilayer membrane. Because they lack a peptidoglycan cell wall, they display highly pleomorphic morphology, appearing as spherical, rod-like, filamentous, or branched forms, with diameters typically in the 0.1–0.3 μm range and the ability to pass through some 0.45 μm pore-size bacterial filters; they are among the smallest free-living prokaryotes known to grow independently. Sterols such as cholesterol in the membrane contribute to membrane stability and resistance to shear and osmotic stress.

(2) Mycoplasma have compact genomes of approximately 0.6–1.4 Mb, encoding only a limited repertoire of metabolic and structural proteins and lacking genes for cell wall biosynthesis as well as multiple complete metabolic pathways. Energy metabolism relies mainly on simplified routes such as glycolysis or arginine degradation; the complete tricarboxylic acid cycle and typical respiratory chain are absent, and there is strong dependence on exogenous nutrients including cholesterol, fatty acids, amino acids, and nucleotides. Growth is relatively slow, with generation times typically ranging from 1 to 6 hours.

1.2 Physicochemical Properties and Antibiotic Susceptibility

(1) Mycoplasma typically behave as Gram-negative organisms and appear as small, pale purple bodies with Giemsa staining. Most strains grow optimally at 35–37 °C within a pH range of 7.0–8.0 and are relatively sensitive to osmotic shifts. They are poorly tolerant of desiccation and heat and can be inactivated relatively quickly at appropriate temperatures, but are susceptible to 75% ethanol and commonly used chlorine-containing disinfectants; conversely, they can survive for extended periods under low-temperature conditions such as −20 °C.

(2) Because they lack a peptidoglycan structure, mycoplasma are intrinsically resistant to cell wall–targeting antibiotics such as penicillins and cephalosporins. Commonly effective agents include macrolides, tetracyclines, and fluoroquinolones, which mainly target protein synthesis or DNA replication. With the emergence of resistance mutations, macrolide resistance rates in Mycoplasma pneumoniae and urogenital mycoplasma have been increasing in some regions, necessitating integration of resistance surveillance data into therapeutic decision-making.

II. Classification of Mycoplasma and Clinically or Experimentally Relevant Species

2.1 Taxonomic Framework

(1) Mycoplasma belong to the class Mollicutes, within which species of greatest relevance to human and animal disease and to laboratory settings are mainly in the genera Mycoplasma and Ureaplasma. The genus Mycoplasma includes multiple pathogens of the human respiratory and urogenital tracts as well as common contaminants in cell culture, whereas Ureaplasma species typically colonize the urogenital tract, contribute to local inflammatory processes, and can survive in in vitro culture systems.

2.2 Common Pathogenic Species and Laboratory Contaminants

(1) Mycoplasma pneumoniae targets respiratory epithelial cells and can cause pharyngitis, bronchitis, and community-acquired pneumonia. Urogenital species such as Ureaplasma urealyticum, Mycoplasma hominis, and Mycoplasma genitalium are associated with non-gonococcal urethritis, cervicitis, pelvic inflammatory disease, infertility, and adverse pregnancy outcomes. Their pathogenicity is based on adhesion protein–mediated colonization, toxic metabolic products, and immune-mediated tissue injury.

(2) In cell culture and livestock production, common contaminating and pathogenic species include oral mycoplasma, Mycoplasma arginini, and others that can persist for long periods in culture systems, consuming nutrients and altering the extracellular environment, thereby interfering with cell proliferation, metabolism, and functional assays. In farm animals and poultry, they can also cause chronic respiratory disease, arthritis, and reduced productivity.

III. Impact of Mycoplasma on Laboratory Cell Culture

3.1 Sources of Contamination and Cryptic Nature

(1) Pathways by which mycoplasma enter cell culture systems include contamination carried by newly introduced cell lines or primary cells; mycoplasma present in untested sera, trypsin solutions, or other biological reagents; aerosols, droplets, or cross-contamination during handling; and residual contamination on incubator interiors, work surfaces, and frequently used instruments.

(2) Unlike typical bacteria, mycoplasma rarely cause obvious turbidity in culture media and generally do not induce rapid, massive cell death, so contamination often goes unnoticed for extended periods. In the absence of systematic routine testing, contamination can slowly spread across multiple cell lines and incubators, ultimately compromising data reliability across an entire experimental platform.

3.2 Effects on Cells and Experimental Readouts

(1) Mycoplasma can adhere to cell surfaces or persist extracellularly, competitively consuming nutrients in the culture medium and releasing metabolic waste products that perturb cellular energy metabolism and homeostasis. Consequences include reduced growth rates, morphological abnormalities, altered adherence, and changes in apoptosis/necrosis rates; in long-term passaged cell lines, contamination may also promote genetic drift and genomic instability.

(2) In functional studies and multi-omics analyses, mycoplasma contamination alters transcriptomic, proteomic, and metabolomic profiles, confounding pathway analysis and drug mechanism studies. In the manufacture of antibody drugs, vaccines, or cell therapy products, mycoplasma-positive cultures not only compromise product quality but also violate regulatory requirements, potentially resulting in batch failures or the need for extensive revalidation.

IV. Strategies for Mycoplasma Detection

4.1 Overall Detection Strategy

(1) From “testing when contamination is suspected” to “scheduled quality control”: In modern cell laboratories, mycoplasma testing should be embedded in routine quality control. All newly received cell lines must be tested for mycoplasma; for core cell lines maintained long term, fixed testing intervals should be defined; before critical experiments or product release, mycoplasma negativity should be reconfirmed to ensure the reliability of data and products.

(2) Combining multiple methods to increase robustness: Mycoplasma detection technologies include culture-based assays, fluorescence staining, PCR/real-time PCR, and enzyme-based signal readout methods. Combining rapid, high-throughput screening methods with highly specific confirmatory techniques can improve testing efficiency and traceability while maintaining sensitivity and specificity.

4.2 Rapid Detection Technologies

(1) Luminescence-based mycoplasma assays typically couple nucleic acid or enzymatic reactions to a luminescent readout, converting the presence of mycoplasma into light intensity that can be measured in microplate formats. These methods are characterized by rapid turnaround, a high degree of automation, and suitability for routine monitoring of large sample numbers, making them particularly useful for cell banks, seed batches, and rapid pre-experiment release testing.

(2) Fluorescence-based mycoplasma assays use specific dyes or fluorescently detected amplification products to generate a signal, providing results within a short time frame. In some methods, fluorescence distribution can be examined microscopically for a direct visual assessment of contamination. Such assays are well suited for routine surveillance and for re-testing suspicious samples.

4.3 Broad-Coverage Detection Solutions

Broad-coverage mycoplasma detection kits are generally designed against conserved targets in Mycoplasma and Ureaplasma, thereby covering a wide range of contamination scenarios and being applicable to mammalian cell lines, primary cells, and certain microbial samples. The workflows are typically streamlined, facilitating routine mycoplasma monitoring under diverse laboratory conditions.

V. Mycoplasma Eradication and Environmental Control

5.1 Strategies for Removing Mycoplasma from Cell Cultures

(1) When a culture tests positive for mycoplasma, decisions should first be based on the importance and replaceability of the cells. For common, easily replaceable cell lines, the preferred option is to discard the contaminated culture and re-establish it from a rigorously tested cell bank. For clinical specimens, highly engineered cells, or materials that are difficult to obtain again, appropriately evaluated chemical or biological eradication protocols may be considered.

(2) Treating contaminated cells over multiple passages with dedicated mycoplasma removal reagents is a commonly used in-culture eradication strategy. During treatment, cell morphology, proliferation rate, and viability must be carefully monitored to avoid irreversible damage. After completing a treatment cycle, repeated testing at different time points with highly sensitive methods is required to confirm complete clearance.

5.2 Decontamination of the Laboratory Environment and Surfaces

(1) Even if intracellular mycoplasma are eradicated, residual contamination on critical contact surfaces—such as incubator walls, biosafety cabinet worktops, pipette exteriors, and door handles—can reintroduce mycoplasma into cultures during subsequent manipulations. Therefore, environmental decontamination must proceed in parallel with in-culture eradication.

(2) In addition to routine use of 75% ethanol and chlorine-containing disinfectants, environment-specific mycoplasma removal products can be applied by spraying or wiping incubator walls, shelves, air ducts, and work surfaces at regular intervals to enhance mycoplasma kill. Periodic high-temperature or UV sterilization further reduces residual environmental risk.

VI. Overview of Related Aladdin Products

Catalog No.	Product Name	Type / Functional Category	Key Application Notes
L1506760	Mycoplasma Detection Kit (Luminescence Assay)	Luminescence-based detection	Suitable for rapid high-throughput screening and release testing of cell banks and seed batches.
M1373547	Mycoplasma Detection Kit (Fluorescence Assay)	Fluorescence-based detection	Used for routine surveillance and re-testing of suspicious samples; short detection turnaround time.
M775086	Mycoplasma Detection Kit	Broad-range detection	Broad-spectrum screening of mycoplasma across multiple cell and sample types.
M743357	UltraBio™ Mycoplasma Removal Spray	Environmental and equipment surface control	For removal of mycoplasma from incubators, biosafety cabinets, worktops, and other critical surfaces.
M751649	UltraBio™ Mycoplasma Removal Reagent	In-culture mycoplasma eradication	Suitable for eliminating mycoplasma from commonly contaminated cell cultures.
M752154	Mycoplasma Prevention Reagent (1000×)	Intracellular prevention	Prophylactic addition for long-term cultures or high-risk cell systems to maintain a low contamination background.
P751569	Mycoplasma Removal Reagent Plus	Enhanced mycoplasma eradication	Designed for intensified clearance in heavily contaminated or hard-to-treat mycoplasma infections.
M752152	Mycoplasma Clearance Reagent (1000×)	Concentrated in-culture eradication	Flexible configuration of mycoplasma removal protocols under diverse culture conditions.
M752155	Mycoplasma Prevention Reagent (2000×)	Highly concentrated prevention	Lower final working concentration; suitable for long-term prevention in systems more sensitive to additives.

Mycoplasma, by virtue of their minute size, streamlined metabolism, and highly cryptic behavior, pose a persistent risk in both clinical and laboratory contexts. A systematic understanding of their biology, combined with integrated detection, eradication, prevention, and environmental control measures, can effectively reduce mycoplasma-related risks at the laboratory level and improve the reliability and safety of cell-based experiments and associated products.

Aladdin: https://www.aladdinsci.com/